Immunotherapy for Alzheimer’s disease: past, present and future
暂无分享,去创建一个
[1] P. Wong,et al. Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects , 2014, Journal of neurochemistry.
[2] H. Galla,et al. Comparison of Five Peptide Vectors for Improved Brain Delivery of the Lysosomal Enzyme Arylsulfatase A , 2014, The Journal of Neuroscience.
[3] Nick C Fox,et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.
[4] E. Siemers,et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.
[5] Anirvan Ghosh,et al. Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle , 2014, Neuron.
[6] F. Tarazi,et al. Bapineuzumab and solanezumab for Alzheimer's disease: is the ‘amyloid cascade hypothesis' still alive? , 2013, Expert opinion on biological therapy.
[7] K. Scearce-Levie,et al. Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier , 2013, Science Translational Medicine.
[8] W. Pardridge,et al. Pharmacokinetics and brain uptake in the rhesus monkey of a fusion protein of arylsulfatase a and a monoclonal antibody against the human insulin receptor , 2013, Biotechnology and bioengineering.
[9] R. Petersen,et al. Can we prevent Alzheimer's disease? Secondary “prevention” trials in Alzheimer's disease , 2013, Alzheimer's & Dementia.
[10] W. Thies,et al. 2013 Alzheimer's disease facts and figures , 2013, Alzheimer's & Dementia.
[11] Qinying Zhao,et al. Safety and Pharmacology of Ponezumab (PF-04360365) After a Single 10-Minute Intravenous Infusion in Subjects With Mild to Moderate Alzheimer Disease , 2013, Clinical neuropharmacology.
[12] Qinying Zhao,et al. Safety and Pharmacology of a Single Intravenous Dose of Ponezumab in Subjects With Mild-to-Moderate Alzheimer Disease: A Phase I, Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Study , 2013, Clinical neuropharmacology.
[13] K. Bales,et al. Chronic administration of an aglycosylated murine antibody of ponezumab does not worsen microhemorrhages in aged Tg2576 mice. , 2012, Current Alzheimer research.
[14] Nick C Fox,et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.
[15] J. Pons,et al. Structural basis of C-terminal β-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease. , 2012, Journal of molecular biology.
[16] K. Blennow,et al. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. , 2012, Archives of neurology.
[17] K. Garber. Genentech's Alzheimer's antibody trial to study disease prevention , 2012, Nature Biotechnology.
[18] N. Toni,et al. An Effector-Reduced Anti-β-Amyloid (Aβ) Antibody with Unique Aβ Binding Properties Promotes Neuroprotection and Glial Engulfment of Aβ , 2012, The Journal of Neuroscience.
[19] K. Blennow,et al. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study , 2012, The Lancet Neurology.
[20] Björn Granseth,et al. Spreading of Neurodegenerative Pathology via Neuron-to-Neuron Transmission of β-Amyloid , 2012, The Journal of Neuroscience.
[21] F. Tarazi,et al. Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors. , 2012, Pharmacology & therapeutics.
[22] F. Barkhof,et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. , 2012, Archives of neurology.
[23] J. Jhamandas,et al. Neuronal receptors as targets for the action of amyloid-beta protein (Aβ) in the brain , 2012, Expert Reviews in Molecular Medicine.
[24] M. Staufenbiel,et al. The Second-Generation Active Aβ Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects , 2011, The Journal of Neuroscience.
[25] W. Luk,et al. Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target , 2011, Science Translational Medicine.
[26] H. Samadi,et al. Solanezumab for Alzheimer's disease , 2011, Expert opinion on biological therapy.
[27] Julie A. Harris,et al. Transsynaptic Progression of Amyloid-β-Induced Neuronal Dysfunction within the Entorhinal-Hippocampal Network , 2010, Neuron.
[28] C. Holmes,et al. Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Aβ42 immunisation in Alzheimer’s disease , 2010, Acta Neuropathologica.
[29] M. Mattson,et al. Involvement of Fc Receptors in Disorders of the Central Nervous System , 2010, NeuroMolecular Medicine.
[30] M. Sierks,et al. Targeted hydrolysis of Beta-amyloid with engineered antibody fragment. , 2010, Current Alzheimer research.
[31] J. Growdon,et al. Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. , 2010, Brain : a journal of neurology.
[32] E. Masliah,et al. Can Alzheimer disease be prevented by amyloid-β immunotherapy? , 2010, Nature Reviews Neurology.
[33] E. Masliah,et al. Can Alzheimer disease be prevented by amyloid-β immunotherapy? , 2010, Nature Reviews Neurology.
[34] M. Sierks,et al. Promoting α‐secretase cleavage of beta‐amyloid with engineered proteolytic antibody fragments , 2009, Biotechnology progress.
[35] W. Schmidt,et al. Development of AFFITOPE vaccines for Alzheimer’s disease (AD) — From concept to clinical testing , 2009 .
[36] W. Pardridge,et al. Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood–brain barrier , 2007, Biotechnology and bioengineering.
[37] I. Verma,et al. Targeted delivery of proteins across the blood–brain barrier , 2007, Proceedings of the National Academy of Sciences.
[38] S. Ferreira,et al. Structure and functions of the human amyloid precursor protein: The whole is more than the sum of its parts , 2007, Progress in Neurobiology.
[39] M. Accavitti-Loper,et al. Amelioration of amyloid load by anti-Abeta single-chain antibody in Alzheimer mouse model. , 2006, Biochemical and biophysical research communications.
[40] O. Almeida. Can we prevent Alzheimer's disease? , 2005, Revista brasileira de psiquiatria.
[41] E. Masliah,et al. β-Amyloid Immunotherapy Prevents Synaptic Degeneration in a Mouse Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.
[42] E. Masliah,et al. Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease , 2005, Neurology.
[43] Y. Lyubchenko,et al. Proteolytic antibody light chains alter beta-amyloid aggregation and prevent cytotoxicity. , 2004, Biochemistry.
[44] N. Hooper,et al. ADAMs family members as amyloid precursor protein α‐secretases , 2003 .
[45] T. Waldmann,et al. Immunotherapy: past, present and future , 2003, Nature Medicine.
[46] R. Motter,et al. Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[47] S. M. Robinson,et al. Passage of amyloid β protein antibody across the blood–brain barrier in a mouse model of Alzheimer’s disease , 2002, Peptides.
[48] B. Hyman,et al. Reversible Memory Loss in a Mouse Transgenic Model of Alzheimer's Disease , 2002, The Journal of Neuroscience.
[49] Xin Wu,et al. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model , 2002, Nature Neuroscience.
[50] Sangram S. Sisodia,et al. γ-Secretase, notch, Aβ and alzheimer's disease: Where do the presenilins fit in? , 2002, Nature Reviews Neuroscience.
[51] D. Wilcock,et al. Number of Abeta inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels. , 2001, DNA and cell biology.
[52] S. Younkin,et al. Reduced effectiveness of Aβ1-42 immunization in APP transgenic mice with significant amyloid deposition , 2001, Neurobiology of Aging.
[53] B. Solomon,et al. Generation of auto-antibodies towards Alzheimer's disease vaccination. , 2001 .
[54] B. Solomon,et al. Generation of autoantibodies towards Alzheimer's disease vaccination , 2000, Neurobiology of Aging.
[55] R. Motter,et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.
[56] H. Braak,et al. Evolution of the neuropathology of Alzheimer's disease , 1996, Acta neurologica Scandinavica. Supplementum.
[57] S. Morrison,et al. Transferrin-antibody fusion proteins are effective in brain targeting. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[58] N. Robakis,et al. An Alternative Secretase Cleavage Produces Soluble Alzheimer Amyloid Precursor Protein Containing a Potentially Amyloidogenic Sequence , 1992, Journal of neurochemistry.
[59] R. Starzyk,et al. Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[60] H. Loetscher,et al. Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. , 2012, Journal of Alzheimer's disease : JAD.
[61] J. Pons,et al. 39-week toxicity and toxicokinetic study of ponezumab (PF-04360365) in cynomolgus monkeys with 12-week recovery period. , 2012, Journal of Alzheimer's disease : JAD.
[62] Kewei Chen,et al. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. , 2011, Journal of Alzheimer's disease : JAD.
[63] D. Selkoe. Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.
[64] E. Masliah,et al. Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. , 2005, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[65] E. Kojro,et al. The non-amyloidogenic pathway: structure and function of alpha-secretases. , 2005, Sub-cellular biochemistry.
[66] H. Braak,et al. Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.
[67] N. Hooper,et al. ADAMs family members as amyloid precursor protein alpha-secretases. , 2003, Journal of neuroscience research.
[68] S. M. Robinson,et al. Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. , 2002, Peptides.
[69] P. S. St George-Hyslop,et al. gamma-Secretase, Notch, Abeta and Alzheimer's disease: where do the presenilins fit in? , 2002, Nature reviews. Neuroscience.
[70] D. Strickland,et al. The mammalian low-density lipoprotein receptor family. , 1999, Annual review of nutrition.
[71] E. Masliah,et al. Structural basis of the cognitive alterations in Alzheimer disease. , 1994 .